Dose Escalation of Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The aim of the study is to evaluate, after radiological progression, efficacy in patients
treated with Sorafenib at a dose of 600 mg bid compared to that in patients treated with best
supportive care.
Primary efficacy objective is progression free survival from randomization.